{"id":680706,"date":"2023-12-11T18:50:02","date_gmt":"2023-12-11T18:50:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680706"},"modified":"2023-12-11T18:50:02","modified_gmt":"2023-12-11T18:50:02","slug":"nonmuscle-invasive-bladder-cancer-nmibc-market-latest-study-by-delveinsight-reveals-a-lucrative-investment-opportunity-and-growth-prospect-abraxis-asieris-astrazeneca-cg-oncolgy-immunitybio","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonmuscle-invasive-bladder-cancer-nmibc-market-latest-study-by-delveinsight-reveals-a-lucrative-investment-opportunity-and-growth-prospect-abraxis-asieris-astrazeneca-cg-oncolgy-immunitybio_680706.html","title":{"rendered":"Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Abraxis, Asieris, AstraZeneca, CG Oncolgy, ImmunityBio"},"content":{"rendered":"
\n
\"Non-Muscle<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Non-Muscle Invasive Bladder Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of NMIBC in the 7MM and the launch of new therapies in the market.<\/div>\n

The high-grade NMIBC pipeline possesses potential drugs in mid and late-stage developments to be launched in the near future. The major key players include Urogen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, and others that hold the potential to create a significant positive shift in NMIBC in the market size and the treatment scenario.<\/em><\/p>\n

DelveInsight’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Muscle Invasive Bladder Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Non-Muscle Invasive Bladder Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Muscle Invasive Bladder Cancer treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Non-Muscle Invasive Bladder Cancer (NMIBC): An Overview<\/strong><\/p>\n

Non-muscle invasive bladder cancer (NMIBC) is cancer of the bladder. NMIBC is a cancer that grows only in the thin tissue on the inside surface of the bladder. With NMIBC, the bladder muscle is not involved, and the tumor does not spread outside the bladder.<\/p>\n

There are a number of things that may increase the risk of getting bladder cancer including smoking, working in places that make plastics, paints, leather, and rubber, cancer drugs, radiation to the pelvis, and genes. Blood in the urine is the most common symptom of bladder cancer, which is often painless. Other symptoms of NMIBC include frequent and urgent urination, pain when you pass urine, pain in your lower abdomen, and back pain.<\/p>\n

The best treatment for NMIBC is early diagnosis and early care. Treatment will also depend on the stage and the growth of cancer. Treatments for non-muscle invasive bladder cancer include cystoscopic transurethral resection of the bladder tumor (TURBT), intravesical therapy, and surgery. If these options fail to treat the cancer, your doctor may recommend removing the complete bladder.<\/p>\n

FDA has approved many drugs for the treatment of bladder cancer but to date there are only two drugs which are being given for the treatment of NMIBC which include KEYTRUDA and ADSTILADRIN,<\/strong> approved in 2020 and 2022, respectively.<\/p>\n

Non-Muscle Invasive Bladder Cancer Market Key Facts<\/strong><\/p>\n